YSB Inc. AI Stock Analysis
Want to see HK:9885 full AI Analyst Report?
YSB Inc. (9885) AI Stock Analysis
YSB Inc.
(HKEX:9885)
The score is primarily driven by improving fundamentals and strong, consistent free cash flow, but is held back by elevated leverage and very thin margins that increase sensitivity to cost and financing conditions. Technicals are neutral-to-weak versus key moving averages, while valuation (moderate P/E and solid dividend yield) provides partial support.
YSB Inc. (9885) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 2.26B
- Dividend Yield
- 3.77%
- Average Volume (3M)
- 617.48K
- Price to Earnings (P/E)
- 10.4
- Beta (1Y)
- 0.54
- Revenue Growth
- 16.99%
- EPS Growth
- 126.15%
- Country
- Hong Kong
- Employees
- 6,950
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Software - Application
YSB Inc. Business Overview & Revenue Model
Company Description
YSB Inc. provides a comprehensive digital platform tailored for the Chinese pharmaceutical sector, supporting a wide array of stakeholders such as drug companies, distributors, vendors, pharmacies, and primary healthcare facilities. Its key offerings...
YSB Inc. Financial Statement Overview
Summary
Income statement shows a turnaround with steady revenue growth and a return to positive EBIT/net income in 2025, supported by consistently positive and rising free cash flow. The main offsets are very thin margins (low earnings cushion) and higher balance-sheet risk from a sharp rise in debt and leverage in 2025.
Income Statement
58NeutralBalance Sheet
49NeutralCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.27B | 20.97B | 17.90B | 16.97B | 14.27B | 10.09B |
| Gross Profit | 2.34B | 2.31B | 1.81B | 1.74B | 1.43B | 913.83M |
| EBITDA | 254.12M | 215.85M | 32.88M | -3.07B | -1.35B | -392.32M |
| Net Income | 184.16M | 152.97M | 30.01M | -3.21B | -1.50B | -501.62M |
Balance Sheet | ||||||
| Total Assets | 7.39B | 7.57B | 6.50B | 5.21B | 4.11B | 3.44B |
| Cash, Cash Equivalents and Short-Term Investments | 3.00B | 3.38B | 1.99B | 1.83B | 1.87B | 1.14B |
| Total Debt | 2.44B | 2.77B | 233.51M | 209.66M | 180.55M | 181.73M |
| Total Liabilities | 5.06B | 5.18B | 4.23B | 3.33B | 8.48B | 6.35B |
| Stockholders Equity | 2.38B | 2.44B | 2.32B | 1.92B | -4.35B | -2.90B |
Cash Flow | ||||||
| Free Cash Flow | 655.93M | 619.46M | 632.46M | 433.65M | 54.49M | -608.06M |
| Operating Cash Flow | 688.97M | 637.70M | 655.86M | 451.20M | 98.20M | -487.09M |
| Investing Cash Flow | -229.17M | -896.27M | -253.58M | -792.95M | 41.07M | -352.80M |
| Financing Cash Flow | -255.91M | -70.97M | -109.81M | 255.34M | 261.93M | 1.12B |
YSB Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9885, the sentiment is Negative. The current price of 3.31 is below the 20-day moving average (MA) of 3.43, below the 50-day MA of 3.45, and below the 200-day MA of 4.03, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.03 is Neutral, neither overbought nor oversold. The STOCH value of 36.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9885.
YSB Inc. Peers Comparison
Overall Rating
HK:026872Outperform
HK:808369Neutral
HK:158867Neutral- HK:988559Neutral
HK:201343Neutral
HK:665739Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0268 | 72Outperform | HKD 31.92B | 108.98 | 3.02% | ― | 16.98% | ― |
| HK:8083 | 69Neutral | HKD 1.44B | 2.94 | 12.42% | ― | 8.65% | ― |
| HK:1588 | 67Neutral | HKD 1.67B | 15.72 | 9.51% | 8.66% | 21.19% | 19.81% |
| HK:9885 | 59Neutral | HKD 2.30B | 10.42 | 7.63% | 3.77% | 16.99% | 126.15% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2013 | 43Neutral | HKD 2.73B | -5.99 | -13.18% | ― | 40.17% | 76.39% |
| HK:6657 | 39Underperform | HKD 3.76B | -36.54 | -6.21% | ― | -3.42% | -13.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9885 | YSB Inc. | 3.31 | -4.20 | -55.91% | |
| HK:8083 | China Youzan | 0.96 | -2.78 | -74.20% | |
| HK:0268 | Kingdee International Software Group Co | 8.90 | -5.79 | -39.41% | |
| HK:2013 | Weimob | 0.63 | -1.48 | -70.24% | |
| HK:1588 | Chanjet Information Technology Co., Ltd. Class H | 5.17 | -2.72 | -34.44% | |
| HK:6657 | Baiwang Co., Ltd. Class H | 10.70 | -7.07 | -39.79% |
YSB Inc. Corporate Events
YSB Inc. Clarifies Share Incentive Plan Details Across 2023–2025 Reports
YSB Inc. has issued a supplemental announcement to its annual reports for 2023, 2024 and 2025, providing additional disclosure on its 2023 Share Incentive Plan as required under Hong Kong Listing Rules. The update focuses on the service provider subl...
YSB Inc. Clarifies Performance Undertaking Linked to Acquisition
YSB Inc. has issued a supplemental announcement clarifying the implications of a new three-year performance undertaking linked to its previously disclosed acquisition of a target company. The company states that failure to meet these performance targ...
YSB Inc. Delivers Profit Surge as Digital Pharma Platform Deepens Market Reach
YSB Inc. reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB10.28 billion, up 4.5% year-on-year, driven mainly by a 5.3% rise in its self-operation business. Profit attributable to owners surged 41.9% to...
YSB Inc. Buys HK$158 Million in Shares to Fund Incentive Plan
YSB Inc. has disclosed that a trustee acting under its 2023 share incentive plan purchased 35,365,600 shares on the market between March 23 and July 21, 2026, at a total consideration of HK$158.8 million and an average price of about HK$4.49 per shar...
YSB Inc. Launches Discretionary Share Buyback Plan Under 2026 Mandate
YSB Inc. has unveiled a voluntary share repurchase plan under its existing 2026 general mandate, authorising buybacks of up to 10% of its issued share capital, capped at HK$100 million and executed on the open market. The company will fund the repurc...
YSB Inc. Reports Integration Progress and Management Commitment on Key Acquisition
YSB Inc. reported progress on integrating a recently acquired target company, highlighting efforts to unify business processes, systems, organizational structures and digital operations. Management emphasized that synergy in supply chain and digital...
YSB Inc. Sets August Board Meeting to Review Interim Results and Possible Dividend
YSB Inc. has called a board meeting for 20 August 2026 to review and approve the group’s interim results for the six months ended 30 June 2026, and to authorize their publication. The agenda also includes consideration of an interim dividend, signali...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026